Home / Stocks / BMY

Bristol-Myers Squibb (BMY, Pharmaceuticals) Stock Valuation & Fair Value Fairly valued

Bristol-Myers Squibb (BMY, Pharmaceuticals) trades at a blended P/E of 9.8, about 43% below its historical normal valuation, with a forward growth estimate of -6.1% and a PEG of —. Analysts' one-year estimates have been hit 45% of the time.

DATA AS OF 2026-08-21
Blended P/E
9.8
Normal P/E
17.4
PEG
—
Fwd growth
-6.1%
Div yield
3.9%
RSI (14)
62.5
Neutral

The Street vs SeerForecast

Wall Street's mean price target for BMY is $66.21 across 24 analysts, 1.2% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: fairly valued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been fairly valued since 2026-06-10.

Price and rating by weekClose moved +16.1 percent from 2026-06-10 to 2026-08-17, with 4 rating changes over 20 recorded weeks.2026-06-10: Fairly valued, close 54.98 (recalculated)2026-06-14: Fairly valued, close 56.49 (recalculated)2026-06-16: Fairly valued, close 55.30 (recalculated)2026-06-21: Fairly valued, close 53.40 (recalculated)2026-07-02: Fairly valued, close 58.13 (recalculated)2026-07-06: Quality business with a solid forward outlook, close 56.70 (recalculated)2026-07-09: Quality business with a solid forward outlook, close 57.94 (recalculated)2026-07-12: Fairly valued, close 57.58 (recalculated)2026-07-13: Fairly valued, close 59.34 (recalculated)2026-07-14: Fairly valued, close 56.95 (recalculated)2026-07-20: Fairly valued, close 60.16 (recalculated)2026-07-22: Fairly valued, close 60.76 (recalculated)2026-07-25: Fairly valued, close 62.09 (recalculated)2026-07-27: Fairly valued, close 62.56 (recalculated)2026-07-31: Quality business with a solid forward outlook, close 65.31 (recalculated)2026-08-03: Quality business with a solid forward outlook, close 65.312026-08-07: Fairly valued, close 64.72 (recalculated)2026-08-10: Fairly valued, close 64.722026-08-14: Fairly valued, close 63.83 (recalculated)2026-08-17: Fairly valued, close 63.8355642026-06-102026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-10P/E 9.2-47%Fairly valued
2026-06-14P/E 9.2-47%Fairly valued
2026-06-16P/E 9.2-47%Fairly valued
2026-06-21P/E 9.2-47%Fairly valued
2026-07-02P/E 9.1-48%Fairly valued
2026-07-06P/E 9.3-46%Quality business with a solid forward outlook
2026-07-09P/E 9.3-46%Quality business with a solid forward outlook
2026-07-12P/E 9.2-47%Fairly valued
2026-07-13P/E 9.2-47%Fairly valued
2026-07-14P/E 9.2-47%Fairly valued
2026-07-20P/E 9.7-44%Fairly valued
2026-07-22P/E 9.7-44%Fairly valued
2026-07-25P/E 9.9-43%Fairly valued
2026-07-27P/E 9.9-43%Fairly valued
2026-07-31P/E 9.9-43%Quality business with a solid forward outlook
2026-08-03P/E 9.9-43%Quality business with a solid forward outlook
2026-08-07P/E 9.7-44%Fairly valued
2026-08-10P/E 9.8-44%Fairly valued
2026-08-14P/E 9.7-44%Fairly valued
2026-08-17P/E 9.6-45%Fairly valued
2026-08-21P/E 9.8-43%Fairly valued ← now

Frequently asked questions

Is Bristol-Myers Squibb stock overvalued?

At a blended P/E of 9.8 versus its historical normal P/E of 17.4, Bristol-Myers Squibb trades about 43% below its typical valuation. tickerseer currently rates it fairly valued.

What is Bristol-Myers Squibb's fair value and PEG?

Bristol-Myers Squibb trades at a blended P/E of 9.8 against a historical normal P/E of 17.4, and a forward growth estimate of -6.1%.

Has tickerseer's rating of Bristol-Myers Squibb changed?

tickerseer's rating has been fairly valued since 2026-06-10.

What is the analyst price target for Bristol-Myers Squibb?

The mean Wall Street price target for Bristol-Myers Squibb is $66.21 across 24 analysts, 1.2% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track BMY free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.